[{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Atropine","moa":"||mAChRs","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0.13,"dosageForm":"Intramuscular Injection","sponsorNew":"Kindeva Drug Delivery \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"Kindeva Drug Delivery \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ Sandoz B2B"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Kindeva Drug Delivery \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Kindeva Drug Delivery \/ Nutriband"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Bol Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"BOL-DP-o-04","moa":"CB receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kindeva Drug Delivery \/ Bol Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Kindeva Drug Delivery \/ Bol Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Kindeva Drug Delivery

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The funding aims to advance the the manufacturing of DuoDote (atropine and pralidoxime chloride). It is indicated for the treatment of poisoning by organophosphorus nerve agents.

                          Product Name : Duodote

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 16, 2025

                          Lead Product(s) : Atropine,Pralidoxime Chloride

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Approved FDF

                          Sponsor : U.S. Department of Health and Human Services

                          Deal Size : $129.0 million

                          Deal Type : Funding

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Kindeva will develop commercial manufacturing processes and clinical supplies for Aversa Fentanyl, integrating Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's fentanyl patch system.

                          Product Name : Aversa Fentanyl

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          May 01, 2024

                          Lead Product(s) : Fentanyl

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Nutriband

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Albuterol sulfate is used to treat or prevent bronchospasm in patients four years and older with reversible obstructive airway disease, such as asthma, and to prevent exercise-induced bronchospasm.

                          Product Name : Proventil HFA

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 16, 2021

                          Lead Product(s) : Salbutamol Sulphate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Sandoz B2B

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Under the agreement, Kindeva will develop novel formulations of BOL Pharma’s cannabinoid based drug products delivered by Kindeva’s metered-dose inhaler (MDI) technology.

                          Product Name : BOL-DP-o-04

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 12, 2020

                          Lead Product(s) : BOL-DP-o-04

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Bol Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank